Corticosteroid dose must be stable or decreasing for at least days prior to the baseline MRI scan
Corticosteroids: If used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Corticosteroids: Patients receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid \r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the days prior to enrollment are not eligible
Subjects receiving corticosteroids must be on a stable or decreasing dose of corticosteroid for the prior days
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the days prior to enrollment are not eligible.
Patients receiving systemic corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of systemic corticosteroid; Note: patients who are using topical or inhaled corticosteroids are eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible
Corticosteroid dose must be stable or decreasing for at least days prior to the baseline MRI scan.
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Corticosteroid dose must be stable or decreasing for at least days prior to the baseline CT or MRI scan
Increasing corticosteroid dose in days prior to administration of first dose of study drug. Symptomatic patients who have stable or decreasing corticosteroid use in the past days may be included
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible.
Patients requiring escalation of the corticosteroid dose will be excluded, but patients receiving a stable or decreasing dose for at least one week will be eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment are not eligible
Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior days are not eligible
Corticosteroids: If used to modify immune adverse events related to prior therapy, ? days must have elapsed since last dose of corticosteroid. Participants receiving corticosteroids, who have not been on a stable or decreasing dose of corticosteroid for at least days prior to enrollment, are not eligible
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior days
At least weeks post-craniotomy ( days for stereotactic biopsy), within days prior to the start of SL-, and on a corticosteroid dosage that has been stable or decreasing for at least days.
Stable dose of corticosteroid >= days prior to registration